Back

Impact of CYP2C19 genotype status on clinical outcomes in patients with symptomatic coronary artery disease, stroke, and peripheral arterial disease

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Pharmacogenetics: a tool to guide clinical decisions Pharmacogenetics ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Dominique Maas

Radboud University Medical Centre, Nijmegen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
The clinical implementation of a de-escalation strategy using CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry
Doctor J. Azzahhafi (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Genome-wide association study of amidoarone-induced hypothyroidism
Mr S. Rand (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Arg389Gly beta-1-adrenergic receptor polymorphism determines neutrophil-stunning-associated cardioprotection by metoprolol
Mr A. Clemente Moragon (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort
Doctor E. Magavern (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacogenetics: a tool to guide clinical decisions
Video

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists
thumbnail
Congress Session
Pharmacogenetics: a tool to guide clinical decisions
thumbnail
Congress Presentation
CYP2C19 genetic variants and coronary atherosclerosis: insights beyond antiplatelet therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources